Form 4: Emmaus Life Sciences Co-President & COO Willis C. Lee Increases Stake in Company

Willis C. Lee, Co-President & COO of Emmaus Life Sciences, Inc., has increased his indirect holdings of common stock through purchases made via his Fidelity Roth IRA.

Summary

• Willis C. Lee, the Co-President & COO of Emmaus Life Sciences, Inc., has reported changes in his beneficial ownership of the company's common stock.
• Between February 26, 2024, and February 29, 2024, Lee's Fidelity Roth IRA acquired a total of 115,200 shares of Emmaus Life Sciences common stock.
• The purchases were made at prices ranging from $0.12 to $0.13 per share.
• Following these transactions, Lee's indirect holdings through his Fidelity Roth IRA amount to 159,400 shares.
• Lee also directly owns 395,124 shares and indirectly owns 241,194 shares through his Fidelity Traditional IRA.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The insider buying suggests confidence, but the scale of the purchases is not large enough to indicate a strong positive signal.

Positives

• The Co-President & COO's increased investment in the company may signal confidence in its future prospects.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and are closely watched by investors for signals about management's view of the company's prospects.

Key Dates

Keywords

beneficial ownership, common stock, Emmaus Life Sciences, Form 4, Willis C. Lee, insider trading